News | Wearables | September 09, 2015

SRI International Licenses DataSpeaks Software for Virtual Clinical Decision-Making

DataSpeaks' proprietary algorithm can generate scores suggesting dose adjustments and medication switches via patient-generated and sensor data

 

DataSpeaks, SRI International, license, SIMA, clinical decision support

September 9, 2015 — SRI International and DataSpeaks Inc. announced that SRI has licensed the Science of Individuality Measurement Algorithm (SIMA) software from DataSpeaks. SRI will integrate SIMA into the development of a secure enterprise system for clinical decision-making.

The SIMA algorithm can transform multiple streams of patient-generated and sensor data (from wearable or implantable devices) into actionable, integrated, and personalized assessments of risks (harms) and benefits for drugs in a patient's regimen. The resulting scores may be used in the future to quickly alert healthcare practitioners about potential needs for dose adjustments and medication switches.

"The unique SIMA analytic software has the capacity to synergize with other SRI platforms as a component of an integrated enterprise system designed to enhance clinical decision-making, thereby maximizing the likelihood of treatment benefit and minimizing the risk of significant side-effects related to drugs," said David Sahner, M.D., senior director, clinical translation, SRI Biosciences. "This offers the hope of major reductions in morbidity, mortality and the over $7 billion in annual healthcare costs related to the use of potentially inappropriate medications."

The in-licensing of the software was enabled by a grant from the Michigan Economic Development Corporation to establish an inter-institutional Center of Innovation focused on personalized medicine and pharmacotherapy in the elderly.

DataSpeaks' proprietary SIMA algorithm applies to multivariate time series data that are becoming ubiquitous with hospital, home, wearable, implanted, and environmental monitoring devices; apps; electronic diaries; and pill monitors. SIMA yields internally standardized scores that quantify evidence for clinically relevant interactions over time as "edges" in network graphs that are computed from data about individual patients.

Additional potential uses of SIMA include improvement of diagnostic taxonomies that may facilitate better prediction and therapy choices, identification of disease mechanisms and new drug development targets, and use in novel clinical trial designs that do not "wash out" individual patient differences.

For more information: www.dataspeaks.com, www.sri.com


Additional Content

News | Wearables

Oct. 6, 2026 — Penumbra, Inc. has announced results from a subset analysis of the landmark STORM-PE randomized ...

Home October 09, 2026
Home
Feature | Wearables | Aaron Timm

Four vital signs make up the traditional core of clinical diagnosis: heart rate, blood pressure, respiratory rate and ...

Home April 06, 2026
Home
News | Wearables

Jan. 13, 2026 — Kestra Medical Technologies, a wearable medical device and digital healthcare company, has announced a ...

Home January 14, 2026
Home
News | Wearables

Nov. 10, 2025 — Kestra Medical Technologies, a wearable medical device and digital healthcare company, has announced ...

Home November 11, 2025
Home
News | Wearables

July 30. 2025 — Cardiosense, a medical AI company, recently announced that the U.S. Food and Drug Administration (FDA) ...

Home July 30, 2025
Home
Subscribe Now